Insilico Medicine Projects First-Half 2026 Profit as AI-Driven Drug Program Reaches Phase III

Insilico Medicine (HKEX: 3696) has issued a profit alert for the first half of 2026, forecasting net income of $33.5 mil...

Read story →

Insilico Medicine and SK Biopharmaceuticals Announce $2.5 B Neuroimmune Drug Discovery Partnership

At the BIO 2026 International Convention in Cambridge, Mass., Insilico Medicine and SK Biopharmaceuticals unveiled a res...

Read story →